Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Cell Therapy With TIL Plus IL-2 +/- Pembrolizumab in Metastatic Melanoma
NCT02621021Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2015
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by National Cancer Institute. Started Dec 2015; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02621021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621021.